201 related articles for article (PubMed ID: 19687404)
1. Ratio of metalloproteinase 2 to tissue inhibitor of metalloproteinase 2 in medullary thyroid carcinoma.
Cavalheiro BG; Junqueira CR; Brandão LG
Arch Otolaryngol Head Neck Surg; 2009 Aug; 135(8):812-7. PubMed ID: 19687404
[TBL] [Abstract][Full Text] [Related]
2. Expression of membrane type 1 matrix metalloproteinase in medullary thyroid carcinoma: prognostic implications.
Cavalheiro BG; Junqueira CR; Brandão LG
Head Neck; 2010 Jan; 32(1):58-67. PubMed ID: 19536854
[TBL] [Abstract][Full Text] [Related]
3. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
4. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
[TBL] [Abstract][Full Text] [Related]
5. Increased matrix metalloproteinases 2 and 9 and tissue inhibitor of matrix metalloproteinase 2 expression is associated with progression from vulvar intraepithelial neoplasia to invasive carcinoma.
Määttä M; Santala M; Soini Y; Turpeenniemi-Hujanen T; Talvensaari-Mattila A
Acta Obstet Gynecol Scand; 2010 Mar; 89(3):380-4. PubMed ID: 20109015
[TBL] [Abstract][Full Text] [Related]
6. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid carcinoma: prognostic implications.
Cavalheiro BG; Junqueira CR; Brandão LG
Thyroid; 2008 Aug; 18(8):865-71. PubMed ID: 18651826
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors.
Sogawa K; Kondo K; Fujino H; Takahashi Y; Miyoshi T; Sakiyama S; Mukai K; Monden Y
Cancer; 2003 Nov; 98(9):1822-9. PubMed ID: 14584061
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma.
Korem S; Kraiem Z; Shiloni E; Yehezkel O; Sadeh O; Resnick MB
Isr Med Assoc J; 2002 Apr; 4(4):247-51. PubMed ID: 12001695
[TBL] [Abstract][Full Text] [Related]
11. Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in the serum of patients with benign and malignant thyroid tumours treated surgically.
Pasieka Z; Stepien H; Czyz W; Pomorski L; Kuzdak K
Endocr Regul; 2004 Jun; 38(2):57-63. PubMed ID: 15497929
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.
Pennanen H; Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
Eur J Haematol; 2008 Oct; 81(4):289-97. PubMed ID: 18616513
[TBL] [Abstract][Full Text] [Related]
13. Immunoexpression and prognostic significance of TIMP-1 and -2 in oral squamous cell carcinoma.
de Vicente JC; Fresno MF; Villalain L; Vega JA; López Arranz JS
Oral Oncol; 2005 Jul; 41(6):568-79. PubMed ID: 15925538
[TBL] [Abstract][Full Text] [Related]
14. Expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in tissues with a diagnosis of childhood lymphoma.
Bozkurt C; Ertem U; Oksal A; Sahin G; Yüksek N; Birgen D
Pediatr Hematol Oncol; 2008 Sep; 25(7):621-9. PubMed ID: 18850474
[TBL] [Abstract][Full Text] [Related]
15. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer.
Iniesta P; Morán A; De Juan C; Gómez A; Hernando F; García-Aranda C; Frías C; Díaz-López A; Rodríguez-Jiménez FJ; Balibrea JL; Benito M
Oncol Rep; 2007 Jan; 17(1):217-23. PubMed ID: 17143501
[TBL] [Abstract][Full Text] [Related]
16. The ratio of MMP-2 to TIMP-2 in hilar cholangiocarcinoma: a semi-quantitative study.
Xiao M; Zhou NX; Huang ZQ; Lu YL; Chen LH; Wang DJ; Chang WL
Hepatobiliary Pancreat Dis Int; 2004 Nov; 3(4):599-602. PubMed ID: 15567754
[TBL] [Abstract][Full Text] [Related]
17. Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis.
de Vicente JC; Lequerica-Fernández P; Santamaría J; Fresno MF
J Oral Pathol Med; 2007 Aug; 36(7):415-24. PubMed ID: 17617835
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
[TBL] [Abstract][Full Text] [Related]
19. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma.
Pennanen H; Kuittinen O; Turpeenniemi-Hujanen T
Eur J Haematol; 2008 Jan; 80(1):46-54. PubMed ID: 18028436
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in bladder carcinoma.
Xu K; Hou S; Du Z
Chin Med J (Engl); 2002 May; 115(5):743-5. PubMed ID: 12133547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
